HK Stock MarketDetailed Quotes
01167 JACOBIO-B
- 1.540
- -0.090-5.52%
Market Closed Nov 22 16:08 CST
1.21BMarket Cap-3061P/E (TTM)
1.620High1.530Low918.60KVolume1.590Open1.630Pre Close1.42MTurnover0.12%Turnover RatioLossP/E (Static)788.82MShares4.15052wk High1.22P/B1.21BFloat Cap1.38052wk Low--Dividend TTM788.82MShs Float25.350Historical High--Dividend LFY5.52%Amplitude1.380Historical Low1.550Avg Price300Lot Size--Div YieldTTM--Div Yield LFY
About JACOBIO-B Company
Garcos Pharmaceutical Group Co., Ltd. is committed to providing patients with breakthrough treatment solutions. The company's vision is to work hand in hand with partners to become a globally recognized leader in drug development. The company's laboratories are located in Beijing, China and Massachusetts, USA, and the experimental platforms have the technology to develop modified inhibitors of protein phosphatase, KRAS, and other transcription factors. Gacos has received investments from several biotechnology-specialized investment institutions, including Qiming Ventures, Lilly Asia Fund, Gao Lin, and Taiwan's Yu Sheng.
Company Profile
Symbol01167
Company NameJACOBIO-B
ISINKYG4987A1094
Listing DateDec 21, 2020
Issue Price14.00
Shares Offered96.48M share(s)
FoundedJun 1, 2018
Registered AddressCayman Islands
Chairmanyinxiang wang
Secretaryqingzhongminghui xue
Audit InstitutionDeloitte Guan Huang Chen Fang Certified Public Accountants
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeWalkers Corporate Limited, 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands
Head Office and Principal Place of Business40th Floor, Dah Sing Finance Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees298
MarketHong Kong motherboard
Phone(010)56315466
Fax(010)56315314
EmailIR@jacobiopharma.com
Websitehttp://www.jacobiopharma.com
Business Garcos Pharmaceutical Group Co., Ltd. is a Chinese investment holding company mainly engaged in the development of new clinical-stage drugs. The company is mainly responsible for the independent discovery and development of innovative oncology treatments. The company's major drug development projects include JAB-3068 and JAB-3312 clinical-stage modified SHP2 inhibitors. The company mainly operates in the domestic market.
Company Executives
- Name
- Position
- Salary
- yinxiang wang
- Chairman, CEOs, Executive Director, Chairman of the Nomination Committee
- 3.42M
- xiaojie wang
- CEO, Executive Director, Remuneration Committee Members, Authorized Representative
- 2.55M
- yunyan hu
- Executive Director, Senior Vice President
- 2.51M
- deli chen
- Non-executive Directors, Audit Committee Members, Remuneration Committee Members, Nomination Committee Members
- --
- ruilin song
- Independent Non-Executive Director, Remuneration Committee Chairman, Nomination Committee Members
- 400.00K
- ge wu
- Independent Non-Executive Director, Nomination Committee Members, Remuneration Committee Members, Audit Committee Members
- 200.00K
- bai lu
- Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members, Remuneration Committee Members
- 150.00K
- yi wang
- Chief Medical Officer
- --
- qing xue
- Joint Company Secretary
- --
- minghui zhong
- Joint Company Secretary, Authorized Representative
- --
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
% Chg
No Data